Core Insights - Select Medical Corporation and the Philadelphia Eagles have renewed their partnership, extending it for multiple years, with NovaCare Rehabilitation continuing as the team's Official Physical Therapy Partner [1] Company Overview - Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the U.S., with 104 critical illness recovery hospitals, 38 rehabilitation hospitals, and 1,917 outpatient rehabilitation clinics as of December 31, 2025 [1] - NovaCare Rehabilitation operates 440 physical therapy centers nationwide, with 150 located in the Delaware Valley [1] Partnership Details - The renewed agreement includes NovaCare serving as the presenting sponsor for fan content on the Eagles' digital platforms, including sweepstakes and post-game content [1] - Additional brand exposure will be provided through radio spots, end zone videoboards, and signage at Lincoln Financial Field during home games [1] - NovaCare will continue its involvement in community programs, such as the Eagles Autism Challenge [1] Strategic Importance - The partnership emphasizes a shared commitment to excellence and enhancing fan experiences, reflecting a strong bond developed over 25 years [1] - The extension allows both organizations to expand their community engagement and partnership initiatives [1]

Core Insights - Centene reported a quarterly loss of $1.19 per share, which was better than the Zacks Consensus Estimate of a loss of $1.25, marking an earnings surprise of +4.76% [1] - The company generated revenues of $49.73 billion for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 3.08% and showing a year-over-year increase from $40.81 billion [2] Financial Performance - Over the last four quarters, Centene has surpassed consensus EPS estimates three times and topped revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is $1.93 on revenues of $48 billion, and for the current fiscal year, it is $2.89 on revenues of $191.31 billion [7] Market Position - Centene shares have declined about 3% since the beginning of the year, while the S&P 500 has only declined by 0.7% [3] - The Zacks Industry Rank for Medical - HMOs, which includes Centene, is currently in the bottom 7% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8] Future Outlook - The company's earnings outlook will be crucial for determining the stock's immediate price movement, with management's commentary on the earnings call being particularly important [3][4] - The estimate revisions trend for Centene was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]

Company Overview - Concentra is the largest occupational health services provider in the United States [3] - The company was originally known as OccuSystems and rebranded to Concentra in the late 1990s [2] - Concentra was sold to Humana in 2011 and later acquired by Select Medical in 2015 [2][3] - The company became publicly traded in July 2024 following a spin-off from Select Medical [3] Leadership - Keith Newton has been with Concentra for 25 years and currently serves as CEO [2] - The leadership team includes CFO Matt DiCanio and SVP of Finance and Strategy Tanner Newton [1]

Industry Overview - The Medical sector is undergoing a significant transformation as it approaches 2026, shifting from a defensive haven to a growth engine driven by innovation and demographic demand [1] - Key trends include the integration of artificial intelligence into clinical workflows, enhancing efficiency and precision in diagnostics and drug discovery [2] - The industry faces cost inflation and regulatory changes, pushing providers towards value-based care and operational innovation, while aging populations and chronic diseases sustain long-term demand [3] Stock Recommendations - Analysts are bullish on three medical stocks: Cencora, Inc. (COR), Addus HomeCare Corporation (ADUS), and Select Medical Holdings Corporation (SEM), due to their operational strength and long-term growth potential [4][5] - All three stocks have a Zacks Rank 2 (Buy), a VGM Score of A, and a market capitalization exceeding $1 billion, with over 70% of brokers rating them as a strong buy or buy [6] Cencora, Inc. (COR) - Cencora is benefiting from higher unit volume and improved sales of GLP-1 drugs and specialty products, with strong performance in Canada and strategic investments in European distribution [10] - The Zacks Consensus Estimate for COR's fiscal 2026 earnings is $17.62 per share, indicating a 10.1% year-over-year increase, with six upward estimate revisions in the past 60 days [12] Addus HomeCare Corporation (ADUS) - Addus provides personal care services to elderly and chronically ill individuals, with stable hiring trends and growing market size due to the cost benefits of home-based healthcare [13] - The Zacks Consensus Estimate for ADUS's 2025 earnings is $6.19 per share, signaling a 17.7% year-over-year growth, followed by a 10.7% increase in 2026 to $6.85 [15] Select Medical Holdings Corporation (SEM) - Select Medical operates critical illness recovery facilities and rehabilitation clinics, with strategic expansions and rising patient admissions driving performance [16] - The Zacks Consensus Estimate for SEM's 2025 earnings is $1.23 per share, indicating a 30.9% year-over-year jump, followed by a 9.9% increase in 2026 to $1.36 [18]

Group 1 - Select Medical Holdings Corporation (NYSE:SEM) is recognized as one of the best dividend stocks to buy, with an average price target suggesting a 34% upside and a Street high indicating a 41% upside [1][2] - The company reported Q3 2025 results with revenue reaching $1,363.4 million, reflecting a year-over-year increase of 7.2%. Revenue growth was noted in critical illness recovery hospitals (4.6%), rehabilitation hospitals (16.2%), and outpatient rehabilitation segments (4.3%) [2] - A cash dividend of $0.0625 per share was paid on November 25, indicating the company's commitment to returning value to shareholders [2] Group 2 - The board announced a share repurchase initiative with a capacity of up to $1 billion, extending the program's duration to December 31, 2027 [3] - For FY2025, Select Medical estimates total revenue between $5.3 billion and $5.5 billion, with Adjusted EBITDA projected between $510 million and $530 million, and diluted EPS expected to range from $1.14 to $1.24 [3] - Select Medical operates hospitals and outpatient clinics across the U.S., specializing in various medical conditions including heart and lung issues, neurological and orthopedic problems, cancer, work-related injuries, pediatric care, and sports rehabilitation [4]

Core Viewpoint - Humana reported better-than-expected Q3 earnings driven by premium growth, but faced challenges with elevated expenses and declining medical memberships [2][4]. Financial Performance - Adjusted earnings per share (EPS) for Q3 2025 were $3.24, exceeding the Zacks Consensus Estimate by 11.3%, although it represented a 22.1% decrease year over year [2]. - Adjusted revenues reached $32.65 billion, marking an 11.4% year-over-year increase and surpassing the consensus estimate by 2.1% [2]. - Total operating expenses rose 12.5% year over year to $32.2 billion, exceeding the estimate of $31.2 billion [4]. Operational Update - Premiums increased by 9.9% year over year to $30.7 billion, beating the Zacks Consensus Estimate by 1.2% [3]. - Services revenues climbed 45.1% year over year to $1.6 billion, exceeding the consensus mark by 15.5% [3]. - Total medical membership decreased by 8.3% year over year to 15 million, falling short of estimates [6]. Segment Performance - The Insurance segment reported adjusted revenues of $31.2 billion, a 9.9% year-over-year increase, driven by improved Medicare premiums and an expanding customer base [5]. - CenterWell revenues grew 16.6% year over year to $5.9 billion, benefiting from higher pharmacy and primary care revenues [7]. Financial Position - As of September 30, 2025, Humana had cash and cash equivalents of $5.4 billion, up from $2.2 billion at the end of 2024 [9]. - Total assets increased to $49.7 billion from $46.5 billion at the end of 2024, while long-term debt rose to $12.6 billion [9]. Future Guidance - Adjusted EPS for 2025 is estimated at around $17.00, indicating a 4.9% increase from 2024, while GAAP EPS is projected to be approximately $12.26, down from earlier estimates [12]. - Total revenues are expected to be at least $128 billion, reflecting an 8.7% increase from 2024 [13]. - Individual Medicare Advantage membership is anticipated to decline by around 425,000 in 2025, with growth expected in other segments [14]. Market Position - Humana's stock has a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [20]. - The company is part of the Zacks Medical - HMOs industry, which has seen mixed performance compared to peers like Select Medical [21].

Core Insights - HCA Healthcare has consistently grown profits for over a decade, outperforming the S&P 500 while remaining undervalued with strong upside potential [3][4] - The company is well-positioned to benefit from the aging U.S. population and increasing healthcare spending [5][6] Industry Trends - The U.S. population aged 65 and older increased by 3.1% year-over-year in 2024, while the population under 18 decreased by 0.2% [6] - The share of the population aged 65 and older has risen from 12% in 2004 to 18% in 2024, indicating a significant demographic shift [6][7] - Healthcare spending is strongly correlated with age, with per capita spending for those aged 85 or older being 8.5 times higher than for children under 18 [9] Company Positioning - HCA Healthcare operates the largest healthcare system in the U.S., with over 190 hospitals and 2,400 ambulatory sites, positioning it for continued profit growth [5][12] - The company has increased its hospital count from 166 in 2014 to 191 by the end of Q3 2025, and its licensed bed count from over 43,000 to over 50,500 [16] Financial Performance - HCA Healthcare has achieved a compounded annual growth rate (CAGR) of 6% in revenue and 7% in net operating profit after tax (NOPAT) since 2007 [18] - The company's Core Earnings grew 14% CAGR from $598 million in 2007 to $6.5 billion in the TTM ended Q3 2025 [19] - HCA Healthcare generated a cumulative $50.4 billion in free cash flow (FCF) from 2014 through Q3 2025, with $10.5 billion generated in the TTM alone [23] Shareholder Returns - HCA Healthcare has paid $4.3 billion in cumulative dividends since 2018 and has increased its quarterly dividends from $0.35 per share in Q1 2018 to $0.72 per share in Q4 2025 [25] - The company repurchased $35.6 billion of shares from 2018 through Q3 2025, with a new $10 billion share repurchase program authorized in January 2025 [26] Challenges - The healthcare industry faces ongoing labor shortages, with projections indicating a global healthcare worker shortage of 10 million by 2030 [29] - Despite rising labor costs, HCA Healthcare has managed to reduce salaries and benefits as a percentage of revenue from 46% in 2020 to 44% in the TTM ending Q3 2025 [31]

Group 1 - U.S. stocks showed mixed performance, with the Dow Jones increasing by approximately 100 points on Tuesday [1] - Abercrombie & Fitch Co reported third-quarter earnings of $2.36 per share, surpassing the analyst consensus estimate of $2.16 per share, and quarterly sales of $1.290 billion, exceeding the consensus estimate of $1.282 billion [1] - Abercrombie & Fitch shares rose sharply by 16.8% to $76.71 following the earnings report and raised FY2025 guidance [2][1] Group 2 - Kohls Corp shares surged by 30.1% to $20.51 after beating third-quarter earnings estimates and raising FY25 guidance [4] - Symbotic Inc experienced a gain of 28% to $70.97 after reporting better-than-expected fourth-quarter financial results and issuing first-quarter sales guidance above estimates [4] - Amentum Holdings Inc shares increased by 18.1% to $29.99 following better-than-expected quarterly financial results [4] Group 3 - Autolus Therapeutics PLC shares rose by 16.5% to $1.44 after receiving UK backing for a new CAR-T cancer therapy [4] - Select Medical Holdings Corp gained 15.6% to $16.20 after receiving a non-binding indication of interest from Robert Ortenzio [4] - Zoom Communications Inc shares increased by 9% to $85.64 after beating third-quarter estimates and raising FY2026 guidance [4]

Core Insights - The company plans to add 395 inpatient rehabilitation beds by 2027 through new openings and strategic additions, including a 45-bed hospital in Temple, Texas, and a 32-bed unit in Orlando, Florida [1][5] - The delay of the 20% transmittal rule by CMS is seen as beneficial, allowing for a favorable revenue adjustment this quarter, with expectations of a smaller impact in future periods due to stabilized labor costs [2][3][29] - Revenue for the third quarter grew over 7% to $1.36 billion, with adjusted EBITDA also increasing over 7% to $111.7 million, and earnings per share from continuing operations rose over 21% to $0.23 [7][12] Development and Expansion - The company opened a fourth rehab hospital in partnership with the Cleveland Clinic, adding 32 new beds, and plans to open additional facilities in 2026 and 2027, including a 76-bed rehab hospital in Jersey City, New Jersey [1][5] - Future development efforts will focus on the inpatient rehabilitation segment, with plans to add two acute rehab units and two neurotransitional units [5][6] Financial Performance - Inpatient rehab hospital revenue increased 16% year over year to $328.6 million, with adjusted EBITDA up 13% to $68 million [7][9] - The outpatient rehab division saw a revenue increase of 4% to $325.4 million, but adjusted EBITDA decreased over 14% to $24.2 million due to a reduction in Medicare reimbursement and unfavorable payer mix [8][9] - The critical illness recovery hospital division's revenue increased over 4% to $609.9 million, with adjusted EBITDA rising over 10% to $56.1 million [9] Regulatory Environment - The CMS's deferment of the expanded Medicare outlier reconciliation criteria is viewed positively, although further reforms are needed to support treatment for high acuity patients [2][4][19] - The fixed loss threshold for outlier payments has increased significantly over the past four years, impacting the ability to accommodate acutely ill patients [16][20] Capital Management - The company ended the quarter with $1.8 billion in debt and $60.1 million in cash, maintaining a net leverage of 3.4 times [10][11] - A cash dividend of $0.0625 per share was approved, reflecting the company's commitment to enhancing shareholder value [6]

Group 1: Select Medical Holdings Corporation (SEM) - Select Medical Holdings Corporation is considered one of the most undervalued small-cap stocks currently available for investment, with a Buy rating and a price target of $21 from Benchmark Co. analyst Bill Sutherland [1] - Bank of America Securities analyst Joanna Gajuk also issued a Buy rating on SEM with a price target of $15, citing the recent delay of the 20% Rule by CMS as a factor that could improve the company's financial outlook for fiscal Q3 2025 [3] - The company operates in medical rehabilitation services, divided into three segments: Critical Illness Recovery Hospital, Rehabilitation Hospital, and Outpatient Rehabilitation [4] Group 2: Market Context and Analyst Insights - RBC Capital raised its price target for QUALCOMM to $20 from $16, maintaining an Outperform rating, indicating that the current stock dislocation presents an attractive entry point for investors [2]